Diabetes Drugs Market to reach USD 118 Billion by 2032

Diabetes Drugs Market to reach USD 118 Billion by 2032

A study published by Towards Healthcare states that the diabetes drugs market is estimated to grow from $61.87 billion in 2022 at 6.7% CAGR (2023-2032) to reach an estimated $ 118 billion by 2032, as a result of the rising prevalence of diabetes, and rising patient support.

More than 75% of diabetic adults reside in countries with low or middle incomes.

The diabetes drugs market refers to the pharmaceutical market dedicated to the development, production, and sale of drugs used for the treatment of diabetes. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels, either due to inadequate production of insulin or the body's inability to effectively use insulin. In 2021, there were approximately 537 million adults living with diabetes, representing 1 in 10 individuals. Projections indicate that this number is expected to increase to 643 million by 2030 and further to 783 million by 2045, emphasizing the alarming growth and global impact of diabetes as a prevalent health condition.

Download White Paper @ https://www.towardshealthcare.com/personalized-scope/5055

Competitive Landscape:

The diabetes drugs market is highly competitive, with several key players competing for market share. These companies focus on developing innovative drugs and treatments to meet the evolving needs of patients with diabetes. Several key players dominate the competitive landscape in this field. To gain a larger share of the market, players are using strategies like investments, alliances, acquisitions, and mergers.

Some major players involved in the diabetes drugs market are 诺和诺德 A/s, Sanofi , Merck & Co. , Inc, 礼来 , 阿斯利康 , Takeda Pharmaceuticals (formerly Nycomed) Company Limited, 勃林格殷格翰 International GmbH, 诺华 , 强生公司 Services, Inc., and Bayer (Schweiz) AG .

Market Segmentation of Diabetes Drugs :

By Drug Class

Insulin

DPP- 4 Inhibitors

GLP-1 Receptor Agonists

SGLT2 Inhibitors

By Diabetes Type

Type 1

Type 2

By Route of Administration

Oral

Subcutaneous

Intravenous

By Distribution Channel

Online pharmacies

Hospital Pharmacies

Retail pharmacies

By Geography

North America

Europe

Asia-Pacific

Latin America

Middle East and Africa

?You can place an order or ask any questions, please feel free to contact us at [email protected]

About Us

We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

要查看或添加评论,请登录

Towards Healthcare的更多文章

社区洞察

其他会员也浏览了